U.S was Insulet’s largest product and service line in fiscal 2025, bringing in $1.92B of $2.71B (71%).
| Product and Service | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S | $884.80M | $1.25B | $1.51B | $1.92B | ||||||||
| U.S. Omnipod | — | — | — | — | ||||||||
| International | $363.00M | $410.10M | $523.40M | $754.30M | ||||||||
| International Omnipod | — | — | — | — | ||||||||
| Drug Delivery | $57.50M | $36.00M | $38.90M | $34.10M | ||||||||
| Total | $1.31B | $1.70B | $2.07B | $2.71B |
Insulet brought in $2.71B from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 30.7% from $2.07B in fiscal 2024. U.S was the largest at $1.92B (70.9%), ahead of International at $754.30M (27.9%) and Drug Delivery at $34.10M (1.3%).
Compared with fiscal 2024, International grew 44.1% to $754.30M and U.S grew 27.2% to $1.92B. From fiscal 2022 to 2025, combined revenue from these lines grew from $1.31B to $2.71B, a compound annual growth rate of 27.5%. U.S's share of the total rose from 67.8% to 70.9%.
United States was Insulet’s largest region in fiscal 2025, bringing in $1.95B of $2.71B (72%).
| Geography | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $942.30M | $1.29B | $1.55B | $1.95B | ||||||||
| International | $363.00M | $410.10M | $523.40M | $754.30M | ||||||||
| All Other | — | — | — | — | ||||||||
| Total | $1.31B | $1.70B | $2.07B | $2.71B |
Insulet brought in $2.71B from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 30.7% from $2.07B in fiscal 2024. United States was the largest at $1.95B (72.1%), ahead of International at $754.30M (27.9%).
Compared with fiscal 2024, International grew 44.1% to $754.30M and United States grew 26.2% to $1.95B. From fiscal 2022 to 2025, combined revenue from these regions grew from $1.31B to $2.71B, a compound annual growth rate of 27.5%. United States' share held steady at about 72.1%.
Nonrelated Party was Insulet’s largest revenue line in fiscal 2025, bringing in $2.20B of $2.71B (81%).
| Related and Nonrelated Parties | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Nonrelated Party | $1.06B | $1.22B | $1.48B | $2.20B | |
| Related Party | $249.90M | $473.70M | $587.80M | $511.60M | |
| Total | $1.31B | $1.70B | $2.07B | $2.71B |
Insulet brought in $2.71B from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 30.7% from $2.07B in fiscal 2024. Nonrelated Party was the largest at $2.20B (81.1%), ahead of Related Party at $511.60M (18.9%).
Compared with fiscal 2024, Nonrelated Party grew 48.0% to $2.20B, while Related Party fell 13.0% to $511.60M. From fiscal 2022 to 2025, combined revenue from these revenue lines grew from $1.31B to $2.71B, a compound annual growth rate of 27.5%. Nonrelated Party's share held steady at about 81.1%.
Insulet (PODD) reports its revenue by product and service, by geography and by related and nonrelated parties. In fiscal 2025, U.S was its largest product and service line, bringing in $1.92B (70.9% of the total), followed by International at $754.30M (27.9%).
U.S was Insulet's largest product and service line in fiscal 2025, bringing in $1.92B, or 70.9% of the $2.71B total across its three product and service lines.
United States was Insulet's largest region in fiscal 2025, bringing in $1.95B, or 72.1% of the $2.71B total across its two regions.
Nonrelated Party was Insulet's largest revenue line in fiscal 2025, bringing in $2.20B, or 81.1% of the $2.71B total across its two revenue lines.
International grew faster than U.S in fiscal 2025, up 44.1% from $523.40M to $754.30M. U.S grew 27.2% to $1.92B.
Every figure comes from Insulet's annual financial filings, as reported. Each line keeps the name Insulet gives it, and years follow its fiscal calendar.
Insulet's revenue by product and service goes back to fiscal 2014, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.